Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary fibrosis.
作者信息
Dempsey Timothy M, Thao Viengneesee, Helfinstine David A, Chang Yu-Hui H, Sangaralingham Lindsey, Limper Andrew H
机构信息
David Grant Medical Center, US Air Force, Travis AFB, Fairfield, CA, USA
Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.
出版信息
Eur Respir J. 2023 Oct 12;62(4). doi: 10.1183/13993003.01299-2023. Print 2023 Oct.
PMID:37678948
Abstract
摘要
相似文献
1
Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary fibrosis.抗纤维化药物对特发性肺纤维化患者影响的真实世界队列评估
Eur Respir J. 2023 Oct 12;62(4). doi: 10.1183/13993003.01299-2023. Print 2023 Oct.
2
Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.真实世界研究分析接受抗纤维化治疗的肺功能保留的特发性肺纤维化患者的进展和生存情况。
Adv Ther. 2021 Jan;38(1):268-277. doi: 10.1007/s12325-020-01523-7. Epub 2020 Oct 24.
3
Mortality benefit with antifibrotics in idiopathic pulmonary fibrosis: real world evidence or bias?抗纤维化药物治疗特发性肺纤维化的死亡率获益：来自真实世界的证据还是偏差？
Eur Respir J. 2021 Mar 18;57(3). doi: 10.1183/13993003.04562-2020. Print 2021 Mar.
4
Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis.特发性肺纤维化二线抗纤维化药物的耐受性和疗效。
Pulm Pharmacol Ther. 2021 Dec;71:102099. doi: 10.1016/j.pupt.2021.102099. Epub 2021 Nov 15.
5
Antifibrotics for COVID-19 related lung fibrosis: Agents with benefits?抗纤维化药物治疗 COVID-19 相关肺纤维化：有效药物？
Adv Respir Med. 2021;89(2):231-233. doi: 10.5603/ARM.a2021.0023.
6
Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics.未接受抗纤维化治疗的特发性肺纤维化患者的死亡率及与呼吸相关的住院情况
Front Med (Lausanne). 2021 Dec 24;8:802989. doi: 10.3389/fmed.2021.802989. eCollection 2021.
7
Antifibrotics Modify B-Cell-induced Fibroblast Migration and Activation in Patients with Idiopathic Pulmonary Fibrosis.抗纤维化药物可改变特发性肺纤维化患者中 B 细胞诱导的成纤维细胞迁移和激活。
Am J Respir Cell Mol Biol. 2021 Jun;64(6):722-733. doi: 10.1165/rcmb.2020-0387OC.
8
Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study.特发性肺纤维化患者用力肺活量下降后继续抗纤维化治疗的效果；一项真实世界的多中心队列研究。
Respir Med. 2022 Jan;191:106722. doi: 10.1016/j.rmed.2021.106722. Epub 2021 Dec 23.
9
Does continuation of antifibrotics before lung transplantation influence post-transplant outcomes in patients with idiopathic pulmonary fibrosis?特发性肺纤维化患者在肺移植前继续使用抗纤维化药物是否会影响移植后的结局？
Interact Cardiovasc Thorac Surg. 2022 Jan 18;34(2):250-254. doi: 10.1093/icvts/ivab237.
10
Real-World Data on Bleeding Risk and Anticoagulation in Patients with IPF Treated with Antifibrotics.接受抗纤维化药物治疗的特发性肺纤维化患者出血风险和抗凝治疗的真实世界数据。
Drug Saf. 2020 Oct;43(10):953-955. doi: 10.1007/s40264-020-00991-8.
引用本文的文献
1
An Eternal Dilemma: Exposing the Impact of Immortal Time Bias on Antifibrotic Effectiveness.一个永恒的困境：揭示永生时间偏差对抗纤维化有效性的影响。
Ann Am Thorac Soc. 2024 Oct;21(10):1383-1384. doi: 10.1513/AnnalsATS.202407-717ED.
2
Enzyme-like nanoparticle-engineered mesenchymal stem cell secreting HGF promotes visualized therapy for idiopathic pulmonary fibrosis in vivo.酶样纳米颗粒工程化间充质干细胞分泌 HGF 促进体内特发性肺纤维化的可视化治疗。
Sci Adv. 2024 Aug 23;10(34):eadq0703. doi: 10.1126/sciadv.adq0703. Epub 2024 Aug 21.
3
Effect of Antifibrotic Use on Mortality in Patients with Idiopathic Pulmonary Fibrosis.抗纤维化药物治疗特发性肺纤维化患者的死亡率影响。
Ann Am Thorac Soc. 2024 Oct;21(10):1407-1415. doi: 10.1513/AnnalsATS.202312-1054OC.
Zotero 插件